Gilead has made another big oncology acquisition, paying $21 billion for US biotech Immunomedics and its potential cancer blockbuster Trodelvy, days before survival data is due to be reveal
Roche’s hopes of extending the use of its PD-L1 inhibitor Tecentriq in triple-negative breast cancer (TNBC) have been dashed by a late-stage trial failure looking at the drug i
NICE has recommended regular NHS funding for Roche’s immunotherapy Tecentriq (atezolizumab) in tough-to-treat advanced triple negative breast cancer in final draft guidance, after a previou
Roche’s Tecentriq still has the market for front-line immunotherapy of triple-negative breast cancer (TNBC) to itself, but maybe not for long after Merck & Co reported good
Merck & Co has unveiled data from its immunotherapy Keytruda that could allow it to gain a foothold in the tough-to-treat triple negative breast cancer (TNBC) indication, and potentiall
